RNF43 and neoplasm: In contrast to the naïve and pazopanib-treated 786-O-PR groups, the pazopanib-treated 786-O-PR group with RNF43 overexpression showed slower tumor growth and a smaller tumor volume (Figs. 7a and 7b).